Finally, the identification of novel predictive biomarkers such as the 'dose' of the mutant FLT3, homozygosity versus heterozygosity for the mutant alleles might help in selecting AML patients ...

Major clinical responses in AML patients receiving single-agent FLT3 inhibitors have been rare, although transient peripheral blood blast reduction is common. Given such biological suggestion and ...

Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to ...

波士顿 - 专注于癌症和纤维化治疗的生物技术公司Galecto, Inc. (NASDAQ: GLTO)宣布战略转向，将重点放在肿瘤学和肝脏疾病上，利用其临床资产GB1211。为配合这一重点，公司从Bridge Medicines获得了BRM-1420的全球权利，这是一种双重ENL-YEATS和FLT3抑制剂，可能为急性髓系白血病（AML）提供新的治疗选择。 公司CEO Hans Schambye ...

The European Commission (EC) has granted approval for Daiichi Sankyo’s Vanflyta (quizartinib) for newly diagnosed fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive acute ...

The FLT3 mutation is expressed in about 30% of AML patients and is associated with a worse prognosis, higher relapse rate, faster progression and shorter overall survival, and FLT3 inhibitors have ...

A new classification model called AML60+ improved risk stratification for older adults with acute myeloid leukemia, which can ...

Assessing FLT3 protein expression in AML cells is crucial for the accurate identification and recruitment of patients for the imminent Phase I clinical trials of the Company's HEMO-CAR-T product ...

The drug has been specifically recommended for routine NHS commissioning in England and Wales as an induction, consolidation and maintenance therapy for newly diagnosed FLT3-ITD-positive disease.

Prevail will buy $350,000 worth of shares in Hemogenyx and will serve as a contract research organization for an upcoming clinical trial in pediatric leukemia.